Answers are grounded in this paper and cite their sources.
Repetitive transcranial magnetic stimulation (rTMS) has been widely used to treat the major depressive disorder (MDD) with a common target over the left dorsolateral prefrontal cortex (DLPFC) [1]. Studies have shown that the left DLPFC targets with better antidepressant efficacy were more negatively correlated with the subgenual cingulate cortex (sgACC), suggesting rTMS efficacy might be improved via functional connectivity (FC)-guided targeting [2–4]. A multi-site rTMS study using the group-average DLPFC target, defined as the most negative FC with sgACC from a cohort of healthy controls, reported a high response rate of 49% in MDD [5].
No takes yet. Share an insight, caveat, or question.
Kong et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: